Half-Year Financial Report
Released
Released
Announcement PDF
IMAGION BIOSYSTEMS LIMITED
ABN: 42 616 305 027
Consolidated Half‐Year Financial Report ‐ 30 June 2022
1
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2022
Directors' Report
The directors present their report, together with the financial statements, on the consolidated entity (referred to
hereafter as the 'consolidated entity') consisting of Imagion Biosystems Limited (referred to hereafter as the 'Company'
or 'parent entity' or ‘Imagion’) and the entities it controlled at the end of, or during the half‐year ended 30 June 2022.
Principal activities
During the financial year the principal continuing activities of the consolidated entity consisted of: Nanotechnology;
Biotechnology; Cancer Diagnostics; and Medical Imaging using Superparamagnetic Relaxometry.
Review of operations
Operating loss for the half‐year of $5,760,270 (30 June 2021 half‐year: $1,450,236 loss) was materially in line with
expectations and increased from the prior half‐year mainly due to the timing of receipt of the R&D tax incentive and
increased expenditure, refer below for further discussion.
Revenue and other income
Revenue and Other Income comprised income generated through sales of nanoparticles manufactured by the
consolidated entity to customers.
Total receipts from sales of super‐paramagnetic iron oxide nanoparticles over the half‐year increased by $105,338 to
$263,152 (30 June 2021 half‐year: $157,814). These sales were undertaken directly through IBX and includes sales to
New Phase, an Israeli‐based company, for the exploratory use of their SaNP hyperthermia treatment as well as initial
sales to new customers.
Research & development tax incentives
Subsequent to year end the consolidated entity lodged and received approval from AusIndustry in relation to its 2021
research and development tax incentive claim. The consolidated entity has lodged its 2021 income tax return
requesting a tax incentive of $2,500,966, which is materially in line with the prior year ($2,612,159). The 2021 claim is
expected to be received within the third quarter of 2022.
Operating expenses
Total expenses increased by $1,794,995 to $6,026,033 (30 June 2021 half‐year: $4,231,038).
Research and development expenses
Research and development expenses increased by $683,890 to $1,771,433 (30 June 2021 half‐year: $1,087,543). Whilst
expenses relating to the MagSense® HER2 Breast Cancer First‐in‐human Study remained relatively consistent there were
increases in other research and development initiatives including: increased animal studies and in‐house R&D
supporting other indications including prostate cancer and brain tumour imaging; outsourced support to increase CMC
and GMP manufacturing capabilities to support further clinical and manufacturing requirements; and expenses in
relation to investigating the use of a non‐targeted nanoparticle to be used in conjunction with conventional Magnetic
Resonance Imaging (MRI) including expenses associated with the Sponsored Research Agreement with Massachusetts
General Hospital.
2
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2022
Employment expenses
Employment expenses increased by $584,196 to $2,213,243 (30 June 2021 half‐year: $1,629,047). In addition to salary
increases and promotions in the ordinary course of business the consolidated entity has increased its organisational
capability with key hires including: Chief Development Officer and other clinical operations employees to increase
clinical operations capabilities as we plan for the next phase of development; Director of Operations to improve
manufacturing capabilities to supporting development plans and external sales; Medical Physicist to increase imaging
capabilities; and a part‐time Marketing and Communications Manager to reduce reliance on outsourced providers.
Other expenses
All other expenses increased by $526,909 to $2,041,357 (30 June 2021 half‐year: $1,514,448). Depreciation and finance
costs increased by $407,976 mainly due lease accounting for the new premises in San Diego with the consolidated entity
taking occupancy in early 2022. Professional fees reduced by $182,905 due to a reduction in recruitment costs (due to
timing) and a reduction in listing and filing fees. General expenses increased by $350,563 mainly due to increased in
rent outgoings, utilities and travel related expenses (as a result of post‐Covid travel recommencing).
Liquidity
The consolidated entity remains in a positive cash position with $8.5 million in cash as at 30 June 2022. This position will
be further supported by the expected inflow of $2.5 million in the third quarter of 2022 in relation to the research and
development tax incentive.
The consolidated entity will use the funds to continue to fund clinical development operations, upcoming costs for its
MagSense® HER2 Breast Cancer First‐in‐human Study, to explore further research and development pipeline
opportunities for its iron‐oxide nanoparticles (including manufacturing), and other operational costs.
Clinical development
MagSense® HER2 Breast Cancer First‐in‐human Study
The consolidated entity continued its MagSense® HER2 breast cancer First‐in‐human 1 study during the half‐year. The
study is continues to recruit through four sites in three states – Monash Health, Austin Health, Royal Brisbane Women’s
Hospital and Lake Macquarie Private Hospital.
The study is investigating the potential for the MagSense® HER2 targeted imaging agent to aid in nodal staging of HER2
positive breast cancer by identifying if tumour cells have metastasized to the lymph nodes.
All enrolled trial patients receive a dose of the MagSense® HER2 targeted imaging agent, followed by exploratory
assessment by two forms of imaging modalities:
• our proprietary magnetic relaxometry imaging method (MRX); and
• a standard magnetic resonance imaging method (MRI).
The primary objective of the study is to investigate the safety and tolerability of the MagSense® injectable imaging
agent. The secondary objective of the study is to provide a preliminary assessment of the effectiveness of the
MagSense® imaging agent in reaching and being detectable in the lymph nodes.
Findings from this study will inform future clinical research efforts and commercial viability.
In March 2022, the consolidated entity released findings from the first five patients who completed the study. The
interim results noted that there had been no safety or tolerability issued reported related to the imaging agent and that
there was evidence that the MagSense® imaging agent is successfully reaching the patient's lymph nodes. Following
release of the interim results enrolment has continued with results in line with prior patients.
3
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2022
An amendment to the study protocol has been approved by the Human Research Ethics Committee during the half‐year
which is now being implemented at each of the study sites. The amendment provides more flexibility for the
investigator to schedule study related procedures and reduces the number of times participants are required to visit the
clinical site, which may facilitate enrolment.
MagSense® imaging agent stability milestone
During the half‐year third party testing of the MagSense® HER2 Breast Cancer imaging agent showed that it had passed
the 18‐month stability benchmark. The consolidated entity has additional R&D data supporting the benchmark finding
and indicating that the product could have a shelf‐life of up to three years. This data, together with the consolidated
entity's pilot manufacturing experience, supports the consolidated entity's plans to develop nanoparticle based imaging
agents that can be made reproducibly with a long stable shelf‐life. This technical achievement bolsters the growing
opportunity for the consolidated entity to market its nanoparticles to commercial partners and to service larger scale
pivotal clinical trials.
Brain tumour imaging and diagnosis
In 2021 the consolidated entity entered into a collaboration with Patrys Limited to investigate the use of a Patrys’ DNA‐
targeting PAT‐DX1 molecule with the consolidated entity’s MagSense® nanoparticle technology to develop an imaging
agent for hard‐to‐diagnose cancers such as brain cancer.
The consolidated entity's in‐house research has demonstrated that the DX1 molecule can be combined with the
consolidated entity's nanoparticles and remain bifunctional. As a result, both the consolidated entity and Patrys have
expanded the collaboration through entering into an engagement with The University of Sydney during the half‐year.
The research collaboration with The University of Sydney will further explore the potential for a MagSense® DX1
imaging agent to detect brain cancers using the university's expertise in models of Glioblastoma Multiforme. The
consolidated entity expects to report in the progress of these studies in 2023.
Prostate cancer imaging
The prostate cancer project continued during the half‐year and has demonstrated encouraging results with a new PSMA
targeting ligand being used to create an imaging agent in conjunction with the consolidated entity's nanoparticles. The
preclinical research is being undertaken in‐house and in collaboration with researchers at Monash University's
Biomedicine Discovery Institute.
The imaging agent, like most radiopharmaceutical PET tracers, utilized a molecule to target the Prostate Specific
Membrane Antigen which is expressed in most forms of Prostate Cancer. But unlike PET tracers, our MagSense®
technology uses our bio‐safe magnetic nanoparticles instead of radioactive tracers, making it a safer alternative for
imaging prostate cancer.
Continuation of preclinical research throughout the remainder of 2022 will provide the potential for the consolidated
entity to enter 2023 with a clearer picture of the feasibility and timeline for developing a prostate cancer imaging agent
for clinical use.
Use of non‐targeted nanoparticles with conventional Magnetic Resonance Imaging (MRI)
During the half‐year the consolidated entity entered into a Sponsored Research Agreement with researchers at
Massachusetts General Hospital to investigate the potential for the consolidated entity's iron oxide nanoparticle
technology to be used in conjunction with conventional MRI.
Gadolinium‐based Contrast Agents (GBCAs) are the primary contrast media products approved for use with MRI for
cardiovascular applications. Certain patient populations such as patients with chronic kidney disease, pregnant women
and paediatric patients often avoid use of GBCAs due to the potential side effects. An iron oxide nanoparticle‐based
agent would be a safe alternative for vascular imaging applications where contrast media are required.
4
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2022
The consolidated entity's research program aims to leverage our underlying know‐how with iron oxide nanoparticle
technology to investigate their possible use for vascular imaging. This would be a non‐targeted nanoparticle with
properties providing for it to remain in circulation to enhance the visualization of arterial and venous blood flow which
is important in diagnosing and treating certain cardiovascular diseases.
New facility
The fit‐out of a new San Diego R&D facility was largely completed by the end of 2021 with the consolidated entity taking
occupancy in early January 2022. This new facility significantly expands the consolidated entity’s internal nanoparticle
research & development capabilities, provides additional manufacturing capacity to support clinical programs and can
be leveraged to generate revenue through third party commercial relationships.
Outlook
As the consolidated entity's MagSense® HER2 Breast Cancer First‐in‐human Study progresses and the consolidated
entity advances its development pipeline, research and development expenditures and employment expenses are
expected to increase on current levels.
The consolidated entity is well positioned to continue the progression of its MagSense® HER2 Breast Cancer First‐in‐
human Study, as well as other indications and collaborations.
Likely developments and expected results of operations
Management expects spending to increase in future periods pending successful results from the consolidated entity's
first in‐human‐trial in relation to HER2 breast cancer which continued throughout the first‐half of 2022 and is expected
to continue throughout the remainder of 2022. The consolidated entity also expects to carry out other research and
development projects throughout the remainder of 2022.
Significant changes in state of affairs
There were no significant changes in state of affairs.
Matters subsequent to the end of the financial half‐year
The impact of the Coronavirus (COVID‐19) pandemic is ongoing and while it has not had a significant impact on the
consolidated entity financially up to 30 June 2022 the pandemic has slowed progress with the pace of its Phase I Clinical
Study. It is not practicable to estimate the potential impact, positive or negative, after the reporting date. The situation
is constantly evolving and is dependent on measures imposed by the Australian and State‐based Governments.
No other matters or circumstances have arisen since the end of the financial period that has significantly affected or
may significantly affect the operations of the consolidated entity, the results of those operations, or the state of affairs
of the consolidated entity in future financial years.
Rounding of amounts
The company is of a kind referred to in Corporations Instrument 2016/191, issued by the Australian Securities and
Investments Commission, relating to 'rounding‐off'. Amounts in this report have been rounded off in accordance with
that Corporations Instrument to the nearest dollar.
5
Imagion Biosystems Limited
Directors' Report
For the half‐year ended 30 June 2022
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out
immediately after this directors' report.
On behalf of the directors
Robert Proulx
Executive Chair
25 August 2022
6
RSM Australia Partners
Level 21, 55 Collins Street Melbourne VIC 3000
PO Box 248 Collins Street West VIC 8007
T +61 (0) 3 9286 8000
F +61 (0) 3 9286 8199
www.rsm.com.au
AUDITOR’S INDEPENDENCE DECLARATION
As lead auditor for the review of the financial report of Imagion Biosystems Limited and its Controlled Entity for
the half year ended 30 June 2022, I declare that, to the best of my knowledge and belief, there have been no
contraventions of:
(i)
the auditor independence requirements of the Corporations Act 2001 in relation to the review; and
(ii)
any applicable code of professional conduct in relation to the review.
RSM AUSTRALIA PARTNERS
B Y CHAN
Partner
Dated: 25 August 2022
Melbourne, Victoria
THE POWER OF BEING UNDERSTOOD
AUDIT | TAX | CONSULTING
RSM Australia Partners is a member of the RSM network and trades as RSM. RSM is the trading name used by the members of the RSM network. Each member of the
RSM network is an independent accounting and consulting firm which practices in its own right. The RSM network is not itself a separate legal entity in any jurisdiction.
RSM Australia Partners ABN 36 965 185 036
Liability limited by a scheme approved under Professional Standards Legislation
7
Imagion Biosystems Limited
Consolidated Statement of Profit and Loss and Other Comprehensive Income
For the half‐year ended 30 June 2022
Revenue
Revenue and other income
Research & development tax incentives
Operating Expenses
Research & development expenses
Employment expenses
Professional fees
General expenses
Share based payments expense
Depreciation expense
Foreign exchange gain/(loss)
Finance costs
Loss before income tax expense
Income tax expense (benefit)
Loss after Income Tax Expense
2022
half‐year
$
2021
half‐year
$
265,763
‐
265,763
168,643
2,612,159
2,780,802
(1,771,433)
(2,213,243)
(413,316)
(684,453)
(342,141)
(515,381)
‐
(86,066)
(6,026,033)
(1,087,543)
(1,629,047)
(596,221)
(333,890)
(388,906)
(190,316)
(1,960)
(3,155)
(4,231,038)
(5,760,270)
(1,450,236)
‐
‐
(5,760,270)
(1,450,236)
385,461
169,080
‐
‐
385,461
169,080
(5,374,809)
(1,281,156)
Cents
(0.0051)
(0.0051)
Cents
(0.0014)
(0.0014)
Other comprehensive income
Items that may be reclassified subsequently to profit or loss
Foreign currency translation reserve
Income tax relating to these items
Other comprehensive income/(loss), net of tax
Total comprehensive Income (loss) for the year Attributable to the
Owners of Imagion Biosystems Limited
Basic earnings (loss) per share
Diluted earnings (loss) per share
These financial statements should be read in conjunction with the accompanying notes.
8
Imagion Biosystems Limited
Consolidated Statement of Financial Position
As at 30 June 2022
Note
30‐Jun‐2022
$
31‐Dec‐2021
$
Current Assets
Cash and cash equivalents
Trade and other receivables
Other current assets
Total Current Assets
8,521,787
61,321
417,040
9,000,148
13,393,768
31,345
343,946
13,769,059
Non‐Current Assets
Property, plant and equipment
Right‐of‐use assets
Total Non‐Current Assets
683,735
4,707,199
5,390,934
346,096
‐
346,096
Total Assets
14,391,082
14,115,155
Current Liabilities
Trade and other payables
Lease liabilities
Employee benefits
Other liabilities
Total Current Liabilities
769,703
1,132,220
153,782
68,142
2,123,847
585,866
15,141
140,462
34,496
775,965
Non‐Current Liabilities
Lease liabilities (NCA)
Employee benefits
Total Non‐Current Liabilities
3,990,918
3,706
3,994,624
30,877
3,034
33,911
Total Liabilities
6,118,471
809,876
Net Assets
8,272,611
13,305,279
56,827,608
3,239,601
(51,794,598)
8,272,611
56,827,608
2,511,925
(46,034,254)
13,305,279
Equity
Issued capital
Reserves
Accumulated losses
Total Equity
2
3
These financial statements should be read in conjunction with the accompanying notes.
9
Imagion Biosystems Limited
Consolidated Statement of Changes in Equity
For the half‐year ended 30 June 2022
Balance as at 1 January 2021
Issued
Capital
$
Reserves
$
Accumulated
Losses
$
Total Equity
$
51,322,126
1,601,289
(40,009,548)
12,913,867
Loss after income tax
Other comprehensive income/(loss) after tax
‐
‐
‐
169,080
(1,450,236)
‐
(1,450,236)
169,080
Total comprehensive income/(loss)
‐
169,080
(1,450,236)
(1,281,156)
Transactions with owners in their capacity as owners
Contributions of equity
1,588,825
Costs of contributions of equity
(1,922)
Transfer from reserves
‐
Share based payments
‐
Balance as at 30 June 2021
52,909,029
‐
‐
‐
388,906
2,159,275
‐
‐
‐
‐
(41,459,784)
1,588,825
(1,922)
‐
388,906
13,608,520
Issued
Capital
$
Reserves
$
Accumulated
Losses
$
Total Equity
$
56,827,608
2,511,925
(46,034,254)
13,305,279
Balance as at 1 January 2022
Loss after income tax
Other comprehensive income/(loss) after tax
‐
‐
‐
385,461
(5,760,270)
‐
(5,760,270)
385,461
Total comprehensive income/(loss)
‐
385,461
(5,760,270)
(5,374,809)
‐
‐
‐
342,141
3,239,527
‐
‐
‐
‐
(51,794,524)
‐
‐
‐
342,141
8,272,611
Transactions with owners in their capacity as owners
Contributions of equity
‐
Costs of contributions of equity
‐
Transfer from reserves
‐
Share based payments
‐
56,827,608
Balance as at 30 June 2022
These financial statements should be read in conjunction with the accompanying notes.
10
Imagion Biosystems Limited
Consolidated Statement of Cash Flows
For the half‐year ended 30 June 2022
Note
2022
half‐year
$
2021
half‐year
$
237,585
(4,983,801)
703
(58,707)
‐
(4,804,220)
88,605
(3,413,015)
12,970
(13,221)
2,612,159
(712,502)
Cash Flows from Investing Activities
Payment for property, plant and equipment
Proceeds from / (payment for) other assets (security deposits)
Net cash outflow from investing activities
(205,475)
38,588
(166,887)
(20,145)
(91,259)
(111,404)
Cash Flows from Financing Activities
Proceeds from the issue of shares
Proceeds from the exercise of options
Transaction costs relation to the issue of shares
Loan from US Government authority
Lease repayments
Net cash inflow from financing activities
‐
‐
‐
‐
(288,958)
(288,958)
‐
1,588,825
(2,114)
‐
(208,366)
1,378,345
Net increase (decrease) in cash and cash equivalents
(5,260,065)
554,439
Cash and cash equivalents at start of year
Effects of exchange rate changes on cash and cash equivalents
13,393,768
388,084
13,200,547
173,137
Cash and cash equivalents at end of year
8,521,787
13,928,123
Cash Flows from Operating Activities
Receipts from customers (inc of sales and other taxes)
Payments to suppliers and employees (inc of sales and other taxes)
Interest received
Interest and other finance costs paid
Government grants and tax incentives
Net cash outflow from operating activities
These financial statements should be read in conjunction with the accompanying notes.
11
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2022
1
Significant accounting policies
These general purpose financial statements for the interim half‐year reporting period ended 30 June 2022 have been
prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the
Corporations Act 2001, as appropriate for for‐profit entities. Compliance with AASB 134 ensures compliance with
International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
All amounts are stated in Australian dollars, unless otherwise stated.
These general purpose financial statements do not include all the notes of the type normally included in annual
financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report
for the year ended 31 December 2021 and any public announcements made by the Company during the interim
reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.
Going Concern
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal
business activities and the realisation of assets and discharge of liabilities in the normal course of business.
As disclosed in the financial statements, the consolidated entity incurred a loss of $5,760,270 and had net cash
outflows from operating activities of $4,804,220 for the half‐year ended 30 June 2022. The consolidated entity is
still in the product development phase recording minimal sales revenue, consequently it is dependent on external
funding to cover ongoing product development and has forecast losses for the next financial year.
These factors indicate a material uncertainty which may cast significant doubt as to whether the consolidated entity
will continue as a going concern and therefore whether it will realise its assets and extinguish its liabilities in the
normal course of business and at the amounts stated in the financial report.
Despite this financial position, the Directors believe that there are reasonable grounds to believe that the
consolidated entity will be able to continue as a going concern after considering the following factors:
•
•
•
The consolidated entity has the ability to implement a cost optimisation plan to reduce discretionary
expenditures if necessary to reduce operating cash requirements;
The Directors are confident that additional funds can be raised through further capital raisings to support
ongoing research and development activities. The consolidated entity has a proven record of being able to
raise funds to support its ongoing activities including successfully raising $14.8 million (net of costs) during
2020 from a combination of rights issues, placements and exercises of options; and
The consolidated entity has historically received some cost relief through the receipt of research &
development income tax incentives and the directors expect this to continue including receipt of the 2021
incentive expected in the third quarter of 2022 with an approximate value of $2.5 million.
Accordingly, the Directors believe that the consolidated entity will be able to continue as a going concern and that it
is appropriate to adopt the going concern basis in the preparation of the financial report.
The financial report does not include any adjustments relating to the amounts or classification of recorded assets or
liabilities that might be necessary if the consolidated entity does not continue as a going concern.
Issued capital
Ordinary shares are classified as equity.
Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net
of tax, from the proceeds.
12
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2022
1
Significant accounting policies (continued)
Share Based Payments
The consolidated entity operates an equity settled share based payment employee incentive scheme. The fair value
of the equity to which employees became entitled is measured at grant date and recognised as an expense over the
vesting period, with a corresponding increase to an equity account.
The cost of transactions settled by share based payments is measured at the fair value of the equity instrument at
the date of the issue, using an appropriate market based valuation model.
Comparatives
The comparative results presented refer to the 6‐month period up to 30 June 2021 for the Statement of Profit or
Loss and Other Comprehensive Income and the Statement of Cash Flows. The Statement of Financial Position
contains a comparative Statement of Financial Position as of the end of the immediately preceding reporting period,
being 31 December 2021.
2
Issued capital
30‐Jun‐22
Shares
1,121,218,534
31‐Dec‐21
Shares
1,121,218,534
30‐Jun‐22
$
56,827,608
31‐Dec‐21
$
56,827,608
Movements in ordinary share capital ‐ 6 months to 30 June 2021
Details
Date
Opening balance
1‐Jan‐22
Closing balance
30‐Jun‐22
Shares
1,121,218,534
1,121,218,534
Issue Price
‐
$
56,827,608
56,827,608
Ordinary shares ‐ fully paid
Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in
proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value
and the company does not have a limited amount of authorised capital.
Listed options
As part of a renounceable rights issue (in April 2020) the Company issued listed options. In April 2020 'IBXOA
options' were issued with an exercise price of $0.03. IBXOA options expire on 28 April 2023. IBXOA options entitle
the holder to convert one option to one ordinary share upon application and payment.
3
Reserves
30‐Jun‐22
$
739,064
2,500,537
3,239,601
Foreign currency translation reserve
Share based payment reserve
31‐Dec‐21
$
353,529
2,158,396
2,511,925
Foreign currency translation reserve
The reserve is used to recognise exchange differences arising from the translation of the financial statements of
foreign operations to Australian dollars. It is also used to recognise gains and losses on hedges of the net
investments in foreign operations.
4
Commitments
The consolidated entity had contracted commitments for services in relation to its MagSense® HER2 Breast Cancer
First‐in‐human Study totalling $70,480. These expenses represent estimated contractual commitments to the
Company's CRO until 31 October 2022 when the contract with the CRO is up for renewal. These expenses are
expected to be incurred within the next 4 months. There are anticipated to be further costs post 31 October 2022
but they aren't yet committed. The consolidated entity had no other commitments (31‐Dec‐21: $460,373).
13
Imagion Biosystems Limited
Notes to the Financial Statements
For the half‐year ended 30 June 2022
5
Contingent liabilities
As of 30 June 2022, the Company was not party to any material litigation, claims or suit whose outcome could have
a material effect on the financial statements (31 December 2021: Nil).
6
Operating segments
Identification of reporting operating segments
The consolidated entity is organised into one operating segment being Research & Development. This operating
segment is based on internal reports that are reviewed and used by the Board of Directors (who are identified as the
Chief Operating Decision Makers (CODM) in assessing performance and in determining the allocation of resources).
Geographical information
The consolidated entity has non‐current assets and derives revenue in two geographical areas as outlined below:
Geographical location of non‐current assets
Property, plant and equipment
United States of America
Australia
Right‐of‐use assets
United States of America
Australia
Geographical derivation of revenue
Revenue and other income
United States of America
Australia
30‐Jun‐22
$
31‐Dec‐21
$
682,581
1,154
683,735
344,711
1,385
346,096
4,707,199
‐
4,707,199
‐
‐
‐
30‐Jun‐22
$
30‐Jun‐21
$
264,935
828
265,763
158,197
10,446
168,643
Research and development tax incentives are derived in Australia.
7
Events after the reporting period
The impact of the Coronavirus (COVID‐19) pandemic is ongoing and while it has not had a significant impact on the
consolidated entity financially up to 30 June 2022 the pandemic has slowed progress with the pace of its Phase I
Clinical Study. It is not practicable to estimate the potential impact, positive or negative, after the reporting date.
The situation is constantly evolving and is dependent on measures imposed by the Australian and State‐based
Governments.
No other matters or circumstances have arisen since the end of the financial period that has significantly affected or
may significantly affect the operations of the consolidated entity, the results of those operations, or the state of
affairs of the consolidated entity in future financial years.
14
Imagion Biosyst
Share your feedback
Discover